Miramel (Pramipexole)

Pramipexole, the active ingredient in Miramel, is a dopamine agonist presented as a tablet for oral use. It stimulates dopaminergic activity in the brain and is used to manage symptoms of Parkinson's disease and restless legs syndrome in adult patients.

GNH USA supplies Miramel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. This includes compliance with EU GMP guidelines and comprehensive documentation for import.

Pramipexole is a dopamine agonist used in the management of movement disorders. - Parkinson's disease: helps control motor symptoms including bradykinesia, rigidity, tremor and improves overall functional mobility in patients with early to advanced stages. - Restless legs syndrome: diminishes uncomfortable sensations and the urge to move the legs, leading to better sleep continuity and reduced daytime fatigue in affected individuals. - Adjunct therapy in Parkinson's disease: used alongside levodopa to lessen motor fluctuations and "off" periods, enhancing overall symptom control.

Pramipexole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Dizziness - Somnolence - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Hallucinations - Impulse control disorders (e.g., compulsive gambling, shopping) - Orthostatic hypotension - Severe skin reactions - Suicidal thoughts or behaviors

When prescribing pramipexole, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose based on renal function assessment. - Psychiatric history: monitor for hallucinations, confusion or mood changes. - Cardiovascular disease: observe for orthostatic hypotension and syncope. - Elderly patients: start with low dose and titrate slowly due to increased sensitivity. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Pramipexole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol, risperidone): may antagonize dopaminergic effects, reducing therapeutic benefit. - MAO‑B inhibitors (e.g., selegiline): can increase dopaminergic activity and risk of hypertensive reactions.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., alcohol, benzodiazepines): may enhance sedation and dizziness. - Antihypertensive agents: additive effect on blood pressure, monitor for hypotension. - Metoclopramide: may counteract pramipexole’s action and increase side effects.